Clinical effects of combination of edaravone, clopidogrel and butylphthalide injection on acute progressive cerebral infarction

X. Zhuang, Shuyan Jiang
{"title":"Clinical effects of combination of edaravone, clopidogrel and butylphthalide injection on acute progressive cerebral infarction","authors":"X. Zhuang, Shuyan Jiang","doi":"10.3760/CMA.J.ISSN.1674-4756.2020.05.034","DOIUrl":null,"url":null,"abstract":"Objective \nTo analyze the clinical effects of combination of edaravone, clopidogrel and butylphthalide injection in the treatment of acute progressive cerebral infarction. \n \n \nMethods \nSeventy-eight patients with acute progressive cerebral infarction treated in Shouguang People’s Hospital from August 2018 to July 2019 were selected and divided into two groups, by random number table method. In the control group, 39 patients were treated with clopidogrel tablets and butylphthalide injection; while 39 patients in the observation group were treated with edaravone based on the treatment of control group. The therapeutic effects, neurological function, daily activities ability were compared between the two groups after treatment; and changes of neuron-specific enolase (NES), S-100β protein, interleukin-1, (IL-1) interleukin-2 (IL-2), interleukin-6(IL-6) were analyzed between the two groups. The incidence of adverse reactions of the two groups were observed and recorded. \n \n \nResults \nAfter treatment, the American National Institute of Health stroke scale (NIHSS) scores of the observation group were significantly lower than those of the control group, and the Barthel index of the observation group was significantly higher than that of the control group (P 0.05). \n \n \nConclusions \nCombined treatment of edaravone, clopidogrel and butylphthalide in jection in patients with acute progressive cerebral infarction can improve the daily activities of patients, reduce nerve damage, and regulate levels of serum S-100β protein, NSE, IL-1, IL-2, IL-6 and other indicators, which has a good application effect. \n \n \nKey words: \nEdaravone; Butylphthalide; Clopidogrel; Acute cerebral infarction","PeriodicalId":9667,"journal":{"name":"Central Plains Medical Journal","volume":"2 1","pages":"114-117"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central Plains Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1674-4756.2020.05.034","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To analyze the clinical effects of combination of edaravone, clopidogrel and butylphthalide injection in the treatment of acute progressive cerebral infarction. Methods Seventy-eight patients with acute progressive cerebral infarction treated in Shouguang People’s Hospital from August 2018 to July 2019 were selected and divided into two groups, by random number table method. In the control group, 39 patients were treated with clopidogrel tablets and butylphthalide injection; while 39 patients in the observation group were treated with edaravone based on the treatment of control group. The therapeutic effects, neurological function, daily activities ability were compared between the two groups after treatment; and changes of neuron-specific enolase (NES), S-100β protein, interleukin-1, (IL-1) interleukin-2 (IL-2), interleukin-6(IL-6) were analyzed between the two groups. The incidence of adverse reactions of the two groups were observed and recorded. Results After treatment, the American National Institute of Health stroke scale (NIHSS) scores of the observation group were significantly lower than those of the control group, and the Barthel index of the observation group was significantly higher than that of the control group (P 0.05). Conclusions Combined treatment of edaravone, clopidogrel and butylphthalide in jection in patients with acute progressive cerebral infarction can improve the daily activities of patients, reduce nerve damage, and regulate levels of serum S-100β protein, NSE, IL-1, IL-2, IL-6 and other indicators, which has a good application effect. Key words: Edaravone; Butylphthalide; Clopidogrel; Acute cerebral infarction
依达拉奉、氯吡格雷、丁苯酞联合治疗急性进展性脑梗死的临床观察
目的分析依达拉奉、氯吡格雷、丁苯酞注射液联合治疗急性进展性脑梗死的临床疗效。方法选择2018年8月至2019年7月在寿光市人民医院住院治疗的急性进展性脑梗死患者78例,采用随机数字表法分为两组。对照组39例患者采用氯吡格雷片联合丁苯酞注射液治疗;观察组39例患者在对照组治疗的基础上加用依达拉奉治疗。比较两组治疗后的疗效、神经功能、日常活动能力;分析两组患者神经元特异性烯醇化酶(NES)、S-100β蛋白、白细胞介素-1、白细胞介素-2 (IL-2)、白细胞介素-6(IL-6)的变化。观察并记录两组患者的不良反应发生情况。结果治疗后,观察组患者美国国立卫生研究院卒中量表(NIHSS)评分显著低于对照组,Barthel指数显著高于对照组(P < 0.05)。结论依达拉芬、氯吡格雷、丁苯酞联合注射治疗急性进展性脑梗死患者,可改善患者日常活动能力,减轻神经损伤,调节血清S-100β蛋白、NSE、IL-1、IL-2、IL-6等指标水平,应用效果良好。关键词:依达拉奉;Butylphthalide;氯吡格雷;急性脑梗死
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信